Compare APC & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APC | SGP |
|---|---|---|
| Founded | 2025 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 884.3M | 910.8M |
| IPO Year | 2025 | 2026 |
| Metric | APC | SGP |
|---|---|---|
| Price | $18.84 | $26.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $21.75 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 147.7K | 61.5K |
| Earning Date | 05-11-2026 | 05-15-2026 |
| Dividend Yield | ★ 10.99% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.47 | N/A |
| Revenue Next Year | $4.20 | N/A |
| P/E Ratio | $40.80 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.08 | $17.06 |
| 52 Week High | $21.72 | $30.56 |
| Indicator | APC | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 40.36 | 65.01 |
| Support Level | $17.65 | $24.87 |
| Resistance Level | $19.49 | $27.23 |
| Average True Range (ATR) | 0.65 | 1.25 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 16.40 | 69.68 |
Arko Petroleum Corp is a fuel distribution company. It operates through three reportable segments: i) Wholesale: Distributes fuel to gas stations, sub-wholesalers, and bulk purchasers, typically under long-term contracts on a cost-plus or consignment basis. ii) Fleet Fueling: Operates proprietary and third-party cardlock locations serving commercial and municipal fleets, and earns commissions from proprietary fuel card sales. iii) GPMP: Supplies fuel to ARKO Retail Sites at cost plus a fixed margin, charges fixed fees to certain sites. The company generates the majority of revenue from the Wholesale segment.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.